Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients

Dr Keith Pratz - Johns Hopkins University, Baltimore, USA

6 Dec 2018

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas

Dr Lorenz Trümper - Georg August University, Göttingen, Germany

6 Dec 2018

Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

$Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )$

6 Dec 2018

Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for children with acute leukaemia

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

6 Dec 2018

Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias

Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA

$Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )$

6 Dec 2018

Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma

Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA

$Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )$

6 Dec 2018

AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML

Prof Marion Subklewe - University of Munich, Munich, Germany

$AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )$